Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 7/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 7/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9182194 | 1.00 | TBXAS1 (0.54) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL9182262 | 0.98 | CYP2C19 (0.58) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL9177719 | 0.98 | CYP2C19 (0.58) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL9181319 | 0.97 | CYP2C19 (0.56) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL9177447 | 0.95 | CYP2C19 (0.60) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL9182839 | 0.95 | CYP2C19 (0.60) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL798439 | 0.95 | TBXAS1 (0.50) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL9347682 | 0.92 | CYP2C19 (0.56) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL9181390 | 0.90 | CYP2C19 (0.60) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL9183939 | 0.90 | CYP2C19 (0.60) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364039-A1 | Methods of Managing Side Effects of a Vasopressin Receptor Antagonist Therapy | UNIV EMORY (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364039-A1 | Methods of Managing Side Effects of a Vasopressin Receptor Antagonist Therapy | UNIV EMORY (US) | 2023-11-16 | — | — | US | disclosed |
| US-11179354-B2 | Substituted cycloalkanes for managing nephrogenic diabetes insipidus | NEPHRODI THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200383940-A1 | Managing Nephrogenic Diabetes Insipidus | EMORY UNIVERSITY | 2020-12-10 | — | — | US | disclosed |
| US-20140142178-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142178-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140121267-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-01 | — | — | US | disclosed |
| US-20140121267-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-01 | — | — | US | disclosed |
| US-8623897-B2 | Methods and compositions for treatment of diabetes and dyslipidemia | KAREUS THERAPEUTICS, SA (CH) | 2014-01-07 | — | — | US | disclosed |
| US-8623897-B2 | Methods and compositions for treatment of diabetes and dyslipidemia | KAREUS THERAPEUTICS, SA (CH) | 2014-01-07 | — | — | US | disclosed |
| WO-2012040177-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071528-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071528-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071528-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | LIPC, PNLIP, LIPA | TBXAS1 555/4885CYP2C19 1051/4885CYP4F2 361/4885 |
| US-20230364039-A1 | Methods of Managing Side Effects of a Vasopressin Receptor Antagonist Therapy | AVPR2, AVPR1A, AVPR1B | TBXAS1 3168/4885CYP2C19 4469/4885CYP4F2 4874/4885 |
| US-20140121267-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | GPR119, FFAR1, INSR | TBXAS1 716/4885CYP2C19 847/4885CYP4F2 1151/4885 |
| US-20200383940-A1 | Managing Nephrogenic Diabetes Insipidus | SLC5A2, SLC5A1, IAPP | TBXAS1 2555/4885CYP2C19 2937/4885CYP4F2 1726/4885 |
| US-20140142178-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | DHCR7, INSR, GPR119 | TBXAS1 1595/4885CYP2C19 885/4885CYP4F2 1069/4885 |
| US-11179354-B2 | Substituted cycloalkanes for managing nephrogenic diabetes insipidus | SLC5A2, SLC5A1, IAPP | TBXAS1 1392/4885CYP2C19 1992/4885CYP4F2 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.